Reuters logo
BRIEF-Genmab and Seattle Genetics to co-develop Tisotumab Vedotin for solid tumors
August 29, 2017 / 10:49 AM / 3 months ago

BRIEF-Genmab and Seattle Genetics to co-develop Tisotumab Vedotin for solid tumors

Aug 29 (Reuters) - GENMAB A/S:

* GENMAB AND SEATTLE GENETICS TO CO-DEVELOP TISOTUMAB VEDOTIN FOR SOLID TUMORS

* COSTS AND PROFITS TO BE SHARED 50:50 GOING FORWARD

* NEWS DOES NOT IMPACT 2017 FINANCIAL GUIDANCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below